Eur Rev Med Pharmacol Sci 2021; 25 (19): 5887-5888
DOI: 10.26355/eurrev_202110_26864

Letter in response to “Polypharmacy is a determinant of hospitalization in Parkinson’s disease”

S. Chu, A. Aamar, S. Hale, A. Roxas, D. Redfearn

Guy’s, King’s, and St. Thomas’ School of Medical Education, King’s College London, UK. stephen.chu@kcl.ac.uk

Free PDF Download

To cite this article

S. Chu, A. Aamar, S. Hale, A. Roxas, D. Redfearn
Letter in response to “Polypharmacy is a determinant of hospitalization in Parkinson’s disease”

Eur Rev Med Pharmacol Sci
Year: 2021
Vol. 25 - N. 19
Pages: 5887-5888
DOI: 10.26355/eurrev_202110_26864

Keywords Related articles:

  1. Polypharmacy is a determinant of hospitalization in Parkinson’s disease
  2. SEMA5A in Parkinson’s disease
  3. Nitric oxide and peroxynitrite serum levels in Parkinson’s disease: correlation of oxidative stress and the severity of the disease
  4. Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson’s disease
  5. Neurodegeneration and cognition in Parkinson’s disease: a review